Physician profile
Scott J Small
NPI 1790784080
$7,073.80
in general payments reported to CMS, 2019-2025
47 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $812 · 2021: $1,641 · 2022: $884 · 2023: $968 · 2024: $1,070 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,222.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,033.11 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $883.05 | 2019-2025 | Vraylar |
| Amgen INC. | $882.57 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $317.40 | 2019-2025 | |
| Lilly USA, LLC | $316.82 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Novartis Pharmaceuticals Corporation | $298.12 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $282.42 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Biohaven Pharmaceuticals, INC. | $262.60 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $202.04 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $194.80 | 2022 | |
| Allergan, INC. | $192.48 | 2019-2020 | |
| Glaxosmithkline, LLC. | $161.64 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amarin Pharma, INC. | $154.08 | 2021-2022 | |
| Silk Road Medical, INC. | $152.38 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Otsuka America Pharmaceutical, INC. | $132.78 | 2022-2024 | Rexulti |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Small listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.